Featured Trial
Our review committee has reviewed this trial and it meets our criteria for going above and beyond. Learn more about featured trials.
Clinical Trial Goal
To find out if SER-155 is safe and works well to reduce infection and GVHD after allogeneic BMT
You may be able to join this trial if you:
- Are 18 years old or older
- Have a disease that can be treated with allogeneic BMT. Some examples include:
- Blood cancer:
- Acute biphenotypic leukemia
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Chronic lymphocytic leukemia (CLL)
- Chronic myeloid leukemia (CML)
- Multiple myeloma
- Myelodysplastic syndromes (MDS)
- Myelofibrosis
- Non-Hodgkin lymphoma (NHL)
- T-cell leukemia
- T-cell lymphoma
- Another cancer that allogeneic BMT may treat
- Other disorder for which allogeneic BMT is known to be a possible treatment
- Blood cancer:
- Are not planning to have an allogeneic BMT using umbilical cord blood (UCB)
- Have not been treated with CAR T-cell therapy
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
SER-155 is a drug made from naturally occurring, healthy bacteria that will replace the bacteria in the gut, which may reduce the risk of infections and GVHD after allogeneic BMT.
Vancomycin is an antibiotic used to treat and prevent bacterial infections.
There are 2 parts to this trial. Part 1 is now fully enrolled. You'll be in Part 2.
Vancomycin is an antibiotic used to treat and prevent bacterial infections.
There are 2 parts to this trial. Part 1 is now fully enrolled. You'll be in Part 2.
- Part 1: Everyone gets SER-155 and vancomycin - Completed
- Part 2: Random assignment to group 1 or group 2 (see below)
In part 2 of this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you and the clinical trial doctors won’t know which group you’re in:
- Group 1 – SER-155 and vancomycin
- Group 2 – Placebo and placebo
Randomized means doctors will use a computer to assign you to either group. A computer assigns you by chance, like flipping a coin or drawing a name out of a hat. You, your doctor or the clinical trial doctor won’t have any control over which group you’ll be assigned. This means you won’t be able to choose your group.
If you are randomized to Group 1, you’ll get:
- SER-155 – Given 1 time each day
- Vancomycin – Given 4 times each day
If you are randomized to Group 2, you’ll get:
- SER-155 Placebo – Given 1 time each day
- Vancomycin Placebo – Given 4 times each day
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for 1 year.
The Food and Drug Administration (FDA) has not yet approved SER-155.
Locations
Sponsors
lead: Seres Therapeutics, Inc., collaborator: Memorial Sloan Kettering Cancer Center
